CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2010-01-01): Rapid HCV response may permit shortened therapy

Clinical

Rapid HCV response may permit shortened therapy

Last Updated: 2010-01-01 9:00:34 -0400 (Reuters Health)

NEW YORK (Reuters Health) - In selected patients with hepatitis C virus (HCV) infection, a shortened 24-week course of pegylated interferon (PEG IFN) and ribavirin can be considered: those with HCV genotype 1, a rapid decrease in viral load, and low HCV RNA at baseline, according to French researchers.

In the January issue of the Journal of Hepatology, Dr. Christophe Moreno of Hopital Claude Huriez, Lille and colleagues conducted a meta-analysis of 7 randomized controlled trials. Six studies compared 24 and 48 weeks of treatment; the remaining study compared 18 and 48 weeks.

Overall, the studies involved 807 treatment naive patients with HCV-1, rapid viral decline (i.e., a 2-log viral load drop or undetectable HCV RNA) within four weeks of treatment. Four hundred ten patients were treated for 48 weeks and 397 for shorter periods.

Sustained virological response rates were lower (mean difference, 13.6%; p=0.004) when treatment was given for less than 48 weeks. Thus, say the investigators, one SVR "would be lost when 7 patients underwent less than 48 weeks of therapy as compared to the expected rate in the 48-week treatment group."

The relapse rate was also significantly higher among patients treated for less than 48 weeks (mean difference, 9.9%).

However, there was no significant effect of shorter treatment duration on the end-of-treatment virological response rate (mean difference, 1.5%).

Also, in the subgroup of patients with undetectable HCV-RNA at week 4 and a baseline HCV-RNA level of no more than 400,000 IU/mL, there was no significant difference between sustained virological responses after 24 or 48 weeks of treatment.

The researchers conclude that these are the only patients who should be considered for shorter treatment. However, they add, "the optimal cut-off defining low baseline viral load and the impact of the presence of other factors capable of altering treatment response, remain subject to debate."

J Hepatol 2010;52:25-31.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.